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Over 25 years ago, it became clear that heart transplan-
tation would become a treatment option for only a limited
group of carefully selected patients with advanced heart
failure (HF) because of limited donor heart organ avail-
ability and restrictive transplant eligibility criteria.1 This
reality energized research focused on clinical applications
of implantable left ventricular assist devices (LVADs) for
long-term mechanical circulatory support (MCS).2,3
Applying LVAD therapy as a bridge to transplant not
only reduced transplant waiting list mortality but also pro-
vided an opportunity to explore the feasibility of longer-
term durable LVAD support for the ultimate application
of LVAD support as permanent therapy.3,4 Experiences
from patients being supported for longer periods for
bridge-to-transplant indication helped establish acceptable
safety criteria of LVADs to support the feasibility for a clin-
ical trial (i.e., Randomized Evaluation of Mechanical Assis-
tances for Treatment of Congestive Heart Failure clinical
trial), establishing an indication for permanent LVAD use
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(destination therapy) for those patients ineligible to receive
a cardiac transplant.3
Historically, adverse event (AE) definitions for device
clinical trials were agreed upon between the United States
Food and Drug Administration (FDA) and device manufac-
turers. These trials were device-specific, with inconsisten-
cies between criteria regarding patient selection, study end-
points, and most importantly, definitions of AEs, making
reliable comparisons between individual trials and devices
problematic. Initiatives to standardize AE definitions for
clinical evaluation of outcomes in the field was initially fos-
tered by registry development, with the MCS device data-
base of the International Society for Heart and Lung
Transplantation (ISHLT), first published in 2003, represent-
ing the earliest effort.5,6 The experience with the ISHLT reg-
istry subsequently led clinicians to pursue the development
of the National Heart, Lung, and Blood Institute supported
Interagency Registry for Mechanically Assisted Circulatory
Support (Intermacs) in 2005.7−9 Intermacs, now maintained
by The Society of Thoracic Surgeons, has become the cor-
nerstone for MCS longitudinal study in the United States,
providing the field with real-world evidence10 and standard-
ized AE definitions. This successful registry endeavor has
led to similar MCS registry endeavors in Europe and Japan
that have adopted similar Intermacs AE definitions, support-
ing the goal of global harmonization.11,12
Incremental improvements in survival on LVAD support
have been demonstrated with nearly 50% of patients surviv-
ing to 5 years.9 However, the persistent burden of key AEs
associated with LVAD therapy seems to have resulted in a
plateau of adoption of durable MCS therapy in the most
recent era and a lack of equipoise for investigating the use
of MCS in the less ill HF population.13 The key AEs that
dominate the LVAD profile include bleeding, infection,
stroke and transient ischemic attack, device malfunction
(particularly device thrombosis and electrical failures), and
right HF and cardiac arrhythmias. These events are associ-
ated with reduced survival, frequent readmission rates, and
higher costs of care.
Recently, AE reporting in device manufacturer-spon-
sored clinical trials has begun to deviate from the previ-
ously established Intermacs AE definitions.14 This provides
a strong incentive for a comprehensive update in AE defini-
tions intended to adopt international standardization and
harmonization. Without such a consensus on standardiza-
tion of event definitions, interpretation of safety data and
adjudication of outcome between clinical trials and in rou-
tine clinical care becomes difficult.
MCS academic research consortium
composition and goals
The renewed interest in developing a consensus between
clinicians, FDA, and device manufacturers for definitions
of AEs stimulated the engagement with the Academic
Research Consortium (ARC).15 The ARC mission state-
ment is focused on promoting informed and collaborative
dialogue across stakeholders, supporting the development
of consensus definitions and nomenclature for targeted
areas of new medical device development, disseminating
such definitions in the public domain.15 Therefore, we con-
vened the MCS-ARC to utilize the expertise of surgeons, HF
cardiologists, infectious disease specialists, nurses, engineers,
and other specialists representing relevant disciplines related
to specific AEs, including infectious diseases, engineering,
HF, and neurology. Comments were also solicited from FDA
and device manufacturers. Although Intermacs collects data
solely on durable MCS devices utilized for bridge-to-trans-
plantation and destination therapy, the MCS-ARC was
encouraged to also provide guidance on AE definitions for
temporary percutaneous devices used primarily in the set-
ting of acute cardiogenic shock and bridge to decision indi-
cations. The collaborative work of the group took place
between November 2017 and December 2018 and included
extensive discussions through conference calls, electronic
communications, and 2 in-person meetings (November 20,
2017, in Washington, DC, and April 11, 2018, in Nice,
France). These forums included the MSC-ARC study
group members and invited international guest participants
from FDA and device manufacturers.
This manuscript summarizes the recommendations of
the MCS-ARC working group. The main goals of the MCS-
ARC include (1) refinement and clarification of current
clinically relevant key AE definitions adopted by Intermacs;
(2) classification of AEs according to type, location, sever-
ity, and timing; (3) use of information provided through
other ARC initiatives, including the Neurologic ARC,16 the
Bleeding ARC,17 and the Valve ARC,18 to adopt and har-
monize AE definitions where possible; (4) provision of
clear guidance for personnel recording the events; and (5)
development of an assignment of cause based largely on
subjective criteria including whether the AE is (1) device-
related; (2) patient-related; or (3) related to management
practices. The goal of this assignment is to provide
improved insight into possible contributing causes of AEs
to develop effective solutions whether they represent
changes to best management practices, refinements to
patient selection or education, or improvements in device
technology. A future goal of the MCS-ARC group will be
to also develop guidelines for MCS clinical trial end-points.
This report focuses on reporting the definitions of key
AEs and the data required to reliably confirm their pres-
ence. The manuscript was intended as a guideline statement
or a guidance document for AE interpretation and docu-
mentation within the field and should be viewed as a road-
map to facilitate the standardization of AE reporting in
future MCS device clinical research and clinical care. As a
living document, the plan is to review the definitions every
2 years and update definitions as necessary.
MCS-ARC adverse events
MCS-ARC bleeding adverse event
Bleeding is the most common AE after LVAD implantation
and is a critical safety measure in all clinical trials utilizing
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these devices.19−22 Data from Intermacs suggest that the
most frequent locations of the first bleeding episode after
implantation is mediastinal (45%), thoracic pleural space
(12%), lower gastrointestinal (GI) tract (10%), chest wall
(8%), and upper GI tract (8%).9,23 Early bleeding relates to
either surgical procedural causes (surgical bleeding) and
the need for early post-operative anti-coagulation or sec-
ondary to coagulation abnormalities that accompany liver
and/or renal dysfunction seen with chronic HF. Following
the peri-operative period, non-surgical bleeding has
emerged as a major source of morbidity and mortality.19−22
The mechanisms responsible for these events include the
development of acquired von Willebrand disease, GI tract
angiodysplasia formation, impaired platelet aggregation,
and anti-coagulation therapy.19−22
The original Intermacs definition of a bleeding AE
included a minimum transfusion requirement to meet the
definition of bleeding during the immediate post-operative
period. The initial criterion of requiring a minimal amount
of blood transfusion to define bleeding was established over
20 years ago as it was recognized that patients with criti-
cally ill HF tended to have inherent coagulopathies that
resulted in peri-operative bleeding, especially when a
patient had undergone previous cardiac surgery before
MCS device implantation. This definition has led to confu-
sion as the primary focus appeared to be more on account-
ing for the number of units of blood transfused as opposed
to identifying a specific bleeding event leading to the trans-
fusion event. For this reason, the group felt it was important
to adopt the bleeding definitions established in the consen-
sus report from the bleeding ARC as the new definition for
the MCS-ARC bleeding AE17 (Table 1 and refer to Supple-
mentary Material Figure S1 available online at www.jhlton
line.org).
Table 1 MCS-ARC Bleeding Adverse Event
 Type 1: Bleeding that is not actionable and does not cause the patient to seek unscheduled performance of studies, hospitalization,
or treatment by a healthcare professional; may include episodes leading to self-discontinuation of medical therapy by the patient
without consulting a healthcare professional. This type is not relevant during a hospitalization.
 Type 2: Any overt, actionable sign of hemorrhage (e.g., more bleeding than would be expected for a clinical circumstance, including
bleeding found by imaging alone) that does not fit the criteria for Type 3, 4, or 5 but does meet at least one of the following criteria:
1. requiring non-surgical, medical intervention by a healthcare professional;
2. leading to hospitalization or increased level of care; or
3. prompting evaluation.
 Type 3
1. Type 3a
& Overt bleeding accompanied by hemoglobin drop of 3 to < 5 g/dl or (1.86−3.1 mmol/liter SI units) (provided hemoglobin drop
is related to bleed)
& Any transfusion with overt bleeding
2 Type 3b
& Overt bleeding plus hemoglobin drop 5 g/dl ((3.1 mmol/liter) or greater (provided hemoglobin drop is related to bleed)
& Cardiac tamponade
& Bleeding requiring surgical intervention for control (excluding dental/nasal/skin/hemorrhoid)
& Bleeding requiring intravenous vasoactive agents
 Type 4: VAD implantation-related bleeding (includes concomitant cardiac or non-cardiac surgical procedures)
1. Reoperation after the closure of incision or incisions used to implant the VAD to control bleeding
2. ≥ 50 kg: ≥ 4U PRBC within any 48 hours during the first 7 days post-implant.
3. < 50 kg: ≥ 20 cm3/kg PRBC within any 24 hours during the first 7 days post-implant.
4. Chest tube output > 2 liters within 24 hours.
 Type 5: Fatal bleeding
1. Type 5a: Probable fatal bleeding; no autopsy or imaging confirmation but clinically suspicious
2. Type 5b: Definite fatal bleeding; overt bleeding or autopsy or imaging confirmation
The association of the bleeding event should be classified as follows:
 Patient-related: (e.g., coagulopathy unrelated to surgical technique such as non-adherence with anti-coagulation medication
resulting in an inappropriately high level of anti-coagulation, hepatic failure)
 Management-related: (e.g., related to surgical technique; hypertension; bleeding in the setting of inappropriate levels of anti-coag-
ulation) or to mismanagement of anti-coagulants.
 Pump related: (e.g., bleeding from the outflow graft, apical connector, or other internal components)
Abbreviations: MCS-ARC Mechanical Circulatory Support, Academic Research Consortium; PRBC, packed red blood cells; VAD, ventricular assist device.
Note: The forms recording the presence of bleeding will continue to record the key sources of bleeding as outlined in the Intermacs User Manual. These
include mediastinal: chest wall; mediastinal: outflow-aorta anastomosis; mediastinal: outflow conduit; mediastinal: inflow conduit; mediastinal: cardio-
pulmonary bypass cannulation site; mediastinal: coagulopathy with no surgical site; mediastinal: other surgical sites; pump or implanted component
pocket (battery or controller); mediastinal: unspecified; pleural space; intra-abdominal; retroperitoneal; pulmonary; genitourinary tract; GI: upper gastro-
intestinal (esophagus, stomach, duodenum, and small bowel); GI: lower gastrointestinal (colon, rectum, and anus); GI: unknown, but guaiac positive
stools; ENT/dental; other.
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MCS-ARC infection adverse event
Infection associated with the implantation of the MCS
device or non-device‒related infection is the second most
common AE seen in LVAD recipients.23−25 The broad defi-
nition adopted by the MCS-ARC group is essentially
unchanged from the current Intermacs definition; however,
a more granular approach was taken in recording the site
and type of infection. In the original Intermacs definition, 4
broad categories were included: (1) localized non-device
infection; (2) percutaneous site and/or pocket infection; (3)
an infection involving any internal pump component and
inflow or outflow tract, including the infection of blood-
contacting surfaces of the LVAD; and (4) sepsis.
The MCS-ARC defines an infection AE as an infection
accompanied by clinical evidence, including pain, fever, or
radiologic findings consistent with infection accompanied
by the need to treat with anti-microbial agents (therapeutic
intent). Guidelines in the database procedure manual will
indicate the importance of obtaining appropriate anti-
microbial therapy guidance from specialists in infectious
diseases. A positive culture from the infected site or organ
should be present unless strong clinical evidence indicates
the need for treatment despite negative cultures or the
absence of culture data. The general categories of infection
for the MCS-ARC Infection AE can be found in Table 226
(Supplementary Material Figure S2 online).
Current Intermacs data forms provide fields for record-
ing major potential locations for infection; however, we
suggest that additional choices that account for newer
implantable components, such as transcutaneous power
elements, implantable controllers, and batteries, will
need to be included. In addition, choices need to be pro-
vided to capture infections related to thoracotomy
approaches for implantation of MCS devices and the sep-
aration of pulmonary infections into pneumonia and
tracheobronchitis.
We recommend that although current data forms capture
the initial organism type (bacterial, fungal, viral, or proto-
zoal), there should be a mechanism to record the species of
organism and if bacterial, whether it is gram-positive or
-negative. Finally, although Intermacs records whether
intravenous antibiotics are used, there is no information on
the duration of use or type of antibiotic. Start and stop dates
for the intravenous drug may be considered.
MCS-ARC neurologic dysfunction adverse event
Neurologic complications are among the most common
AEs seen in patients with MCS and are strongly associated
with disability, impaired quality of life, and mortality.9,27,28
The MCS-ARC has adopted several new or revised defini-
tions for neurologic events compared with previous itera-
tions of Intermacs definitions. These changes align
definitions and ascertainment methodology with other
recent ARC statements addressing neurologic outcomes fol-
lowing cardiovascular procedures with several additions
and adaptations that are required to best serve the unique
patient population, disease state, devices, and procedures
associated with MCS.16,29
Patients receiving MCS may experience central nervous
system (CNS) injury, including ischemic infarction, hemor-
rhage, or hypoxic-ischemic injury. These CNS injuries may
be associated with neurologic symptoms that are concor-
dant with the anatomic location of injury (overt). Alterna-
tively, CNS injury may be asymptomatic (covert) if it is
noted on screening brain imaging or if the anatomic distri-
bution of injury does not match the neurologic symptoms
that led to an imaging study. It will be important to realize
that if an imaging study reveals an area of brain injury and
if on closer neurologic assessment, a symptom is discov-
ered, then the event may be re-adjudicated as overt. In addi-
tion, patients may develop neurologic dysfunction without
evidence of infarction on brain imaging (e.g., transient
ischemic attack or encephalopathy and/or delirium).
Table 3 outlines the MCS-ARC neurologic dysfunction
AE categories of neurologic dysfunction organized as overt
(Type 1), covert (Type 2), or neurologic dysfunction with-
out evidence of injury (Type 3). Importantly, although sub-
dural hematoma is not classically considered a stroke, it is a
common complication seen in patients receiving MCS,
accounting for 13% to 22% of cases of intracranial
hemorrhage.28,30,31 Thus, the MCS-ARC neurologic dys-
function AE includes a description of overt symptomatic
sub-dural hemorrhage (Type 1f), and sub-dural hemorrhage
is included among the possible types of covert CNS hemor-
rhage (Type 2b) if no symptoms are noted.
Clinicians caring for patients with MCS are strongly
encouraged to obtain neuroimaging if a neurologic event is
suspected and the patient is stable enough to obtain the
study. Magnetic resonance imaging will not be an option
owing to the incompatibility with durable MCS devices;
thus, head CT will be the preferred study. Fortunately, CT is
equally sensitive to acute intracranial hemorrhage as mag-
netic resonance imaging, and this has the greatest potential
impact on management. If the initial study is non-diagnostic
and symptoms persist with continued suspicion for CNS
injury, a repeat head CT 24‒48 hours after the onset of
symptoms will have a higher yield for evidence of ischemia.
Clinicians caring for patients with MCS are strongly encour-
aged to obtain neurology consultation if CNS injury is sus-
pected, so that a thorough neurologic assessment can be
performed and documented and interventions initiated, if
appropriate. If a stroke is suspected, a National Institutes of
Health Stroke Scale and modified Rankin score should be
performed to establish the severity of symptoms and disabil-
ity.32 Table 4 provides definitions for acute CNS injury
severity, based on a National Institutes of Health Stroke
Scale assessment32 and recovery, based on a modified Ran-
kin score33 (Supplementary Material Figure S3 online).
Somewhat unique to the population of patients receiving
MCS is that catastrophic HF may lead to CNS injury before
the use of MCS. In addition, CNS injury may occur with
the procedure to implant the MCS device, during ongoing
use of MCS, or when the device is removed. Finally, given
that anti-coagulation is required for MCS and acquired von
Willebrand deficiency and thrombocytopenia are common,
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Table 2 MCS-ARC Infection Adverse Event
1. Percutaneous lead site infections
 Superficial percutaneous lead infection: A positive culture from the skin surrounding the percutaneous lead when there is clinical evidence of
infection such as pain, fever, drainage, erythema, or leukocytosis coupled with the need to treat with anti-microbial therapy. The percutaneous
lead exit site may have drainage and/or the surrounding skin may have erythema. The epithelialization of the percutaneous lead exit site is pre-
served. The gram stain of the skin specimen at the driveline exit site will contain white blood cells (i.e., positive sign for inflammation).
 Deep percutaneous lead infection: A positive culture from the driveline exit site deep to the epithelium, when there is clinical evidence of infec-
tion such as pain, fever, drainage, erythema, or leukocytosis coupled with the need to treat with anti-microbial therapy. The epithelialization of
the percutaneous lead exit site is disrupted and no longer preserved or intact, or there is radiographic evidence of findings consistent with infec-
tion along the path of the percutaneous lead outside the mediastinum.
2. Infection of external surfaces of an implantable componenta: A positive culture from the tissue surrounding the external housing of a pump or one
of its components implanted within the body (including device components such as controllers, batteries, etc.), when there is clinical evidence of
infection such as pain, fever, drainage, erythema, or leukocytosis coupled with the need to treat with anti-microbial therapy.
3. Infection of blood-contacting surfaces of an implantable component (device endocarditis)a: Infection of blood-contacting internal surfaces of
the MCS device including inflow/outflow grafts: documented by positive blood cultures or radiographic or echocardiographic evidence of vegetation
in blood flow path of the pump coupled with the need to treat with anti-microbial therapy.
Non−MCS-related infections.
1. Infective Endocarditis: Non−MCS related
 Positive blood cultures and echocardiography findings for mass or vegetation only on native valves, ICD, or pacemaker leads.
2. BSI
 Positive blood cultures with no other source identified
 Bloodstream infection: non-VAD site or central venous catheter-related (definition from the Centers for Disease Control/National Healthcare Safety
Network)47
Should be coupled with the need to treat with anti-microbial therapy.
3. Mediastinitisa
 Procedure-related mediastinitis
○ Deep sternal wound infection (isolated).
○ Deep sternal wound infection involving MCS device components (continuous with mediastinum or already situated in the mediastinum). Maybe
contiguous with implanted components of the MCS device
 Non−MCS-related mediastinitis:
○ Mediastinitis definitively owing to another cause (e.g., esophageal perforation during endoscopy, contiguous with empyema).
 Superficial mediastinal or thoracotomy wound infection
○ Infection involving only skin, sub-cutaneous fat, and muscle of implant incision.
Should be coupled with the need to treat with anti-microbial therapy.
4. Sepsis
 Life-threatening organ dysfunction caused by a dysregulated host response to infection with:
○ Evidence of systemic involvement by infection, manifested by need to treat with anti-microbial therapy
○ Positive blood cutures and/or two of the following:
& PaO2/FIO2 < 400 or respiratory rate ≥ 22/min or ventilated respiratory support
& Hypotension with systolic BP < 100 mm Hg or MAP ≤ 65 mm Hg.
& Platelet count < 150 or elevated prothrombin time or fibrinogen degradation products
& Bilirubin (serum) > 50% above baseline
& Altered mental status (Glasgow score < 15)
& Creatinine (serum) > 50% above baseline
& Need for intravenous vasoconstricting agents
& For pediatric patients:
 Hypotension defined as a decrease by 15 mm Hg systolic or mean BP, as compared with baseline
 Platelet count < 150, or elevated PTT or FDP
 Bilirubin increased by 50% from baseline
 Creatinine increased by 50% from baseline
 Altered mental status
5. Localized nonMCS device infectiona
 Infection localized to a site not involving the MCS device or components (e.g., pneumonia, urinary tract infection, cholecystitis, diverticulitis,
dental abscess) coupled with the need to treat with anti-microbial therapy
The association of the infection event should be classified as:
 Patient-related: (e.g., non-adherence or poor management of driveline exit site or indwelling catheters, IV drug abuse, aspiration)
 Management-related: (e.g., improper tunneling, contamination of the intraoperative site, prolonged intubation)
 Device-related: (e.g., Device endocarditis diagnosed by radiological examination or detection of pannus within the conduits or device)
Abbreviations: BP, blood pressure; BSI, bloodstream infection; FDP, fibrinogen degradation product; FIO2, fraction of inspired oxygen; ICD, implantable cardio-defibrillator;
IV, intravenous; MAP, mean arterial pressure; MCS-ARC, Mechanical Circulatory Support, Academic Research Consortium; PaO2, partial pressure of oxygen; PTT, partial thrombo-
plastin time; VAD, ventricular assist device.
a
A positive culture from the infected site or organ should be present unless strong clinical evidence indicates the need for treatment despite negative cultures.
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Table 3 MCS-ARC Neurologic Dysfunction Adverse Event
Type 1 Overt CNS injury: acutely symptomatic brain or spinal cord injury
Type 1a Ischemic stroke Sudden onset of neurologic signs or symptoms fitting a focal or multifocal vascular territory within the brain, spinal cord, or retina, that:
1) persist for ≥ 24 hours or until death, with pathology or neuroimaging evidence that demonstrates either:
a) CNS infarction in the corresponding vascular territory (with or without hemorrhage); or
b) absence of other apparent causes (including hemorrhage), even if no evidence of acute ischemia in the corresponding vascular territory is detected.
or
2) Symptoms lasting < 24 hours with pathology or neuroimaging confirmation of CNS infarction in the corresponding vascular territory. Note: when CNS infarction location does not match the tran-
sient symptoms, the event would be classified as covert CNS infarction (Type 2a) and a TIA (Type 3a), but not an ischemic stroke.
Signs and symptoms consistent with stroke typically include an acute onset of one of the following: focal weakness and/or numbness, impaired language production or comprehension, homonymous
hemianopia or quadrantanopia, diplopia, altitudinal monocular blindness, hemispatial neglect, dysarthria, vertigo, or ataxia.For pediatric patients, generalized symptoms such as seizure, irritability,
or altered wakefulness may be accepted as confirmation of acute stroke if imaging or pathology demonstrates previously undocumented CNS infarction.
Sub-type 1aH Ischemic stroke with
hemorrhagic
conversion
Ischemic stroke includes hemorrhagic conversions. These should be sub-classified as Class A or B when an ischemic stroke is the primary mechanism and pathology, or neuro-
imaging confirms a hemorrhagic conversion.
Class A Petechial (non−space-occupying) hemorrhage: Petechiae or confluent petechiae within the infarction or its margins, but without a space-occupying effect.
Class B Confluent (space-occupying) hemorrhage: Confluent hemorrhage or hematoma originating from within the infarcted area with space-occupying effect.
Type 1b Symptomatic intracere-
bral hemorrhage
Rapidly developing neurologic signs or symptoms (focal or global) caused by an intraparenchymal, intraventricular, spinal cord, or retinal collection of blood, not caused by
trauma.
Type 1c Symptomatic sub-arach-
noid hemorrhage
Rapidly developing neurologic signs or symptoms (focal or global) and/or headache caused by bleeding into the sub-arachnoid space, not caused by trauma.
Type 1d Stroke, not otherwise
specified
An episode of acute focal neurologic signs or symptoms and/or headache presumed to be caused by CNS ischemia or CNS hemorrhage, persisting ≥ 24 hours or until death, but
without sufficient evidence to be classified as one of the above (i.e., no neuroimaging performed).
Type 1e Symptomatic hypoxic-
ischemic injury
Non-focal (global) neurologic signs or symptoms due to diffuse brain, spinal cord, or retinal cell death (confirmed by pathology or neuroimaging) in a non-vascular distribu-
tion, attributable to hypotension and/or hypoxia.
Type 1f Symptomatic sub-dural
hemorrhage
An episode of acute focal neurologic signs or symptoms and/or headache accompanied by evidence of bleeding into the sub-dural space.
Type 2 Covert CNS injury: Acutely asymptomatic brain or spinal cord injury detected by neuroimaging
Type 2a Covert CNS infarction Brain, spinal cord, or retinal cell death attributable to focal or multifocal ischemia on the basis of neuroimaging or pathologic evidence of CNS infarction, without a history of
acute neurologic symptoms consistent with the lesion location.
Sub-type 2aH Covert CNS infarction
with hemorrhagic
conversion
Covert CNS infarction includes hemorrhagic conversions. These should be sub-classified as Class A or B when CNS infarction is the primary mechanism and neuroimaging, or
pathology confirms a hemorrhagic conversion.
Class A Petechial (non−space-occupying) hemorrhage Petechiae or confluent petechiae within the infarction or its margins, but without a space-occupying effect
Class B Confluent (space-occupying) hemorrhage: Confluent hemorrhage originating from within the infarcted area with space-occupying effect
Type 2b Covert CNS hemorrhage Neuroimaging or pathologic evidence of CNS hemorrhage within the brain parenchyma, sub-arachnoid space, sub-dural space, ventricular system, spinal cord or retina on neu-
roimaging that is not caused by trauma, without a history of acute neurologic symptoms consistent with the bleeding location.
Type 3 Neurologic dysfunction (acutely symptomatic) without CNS injury
Type 3a TIA Transient focal neurologic signs or symptoms (lasting < 24 hours) presumed to be owing to the focal brain, spinal cord, or retinal ischemia, but without evidence of acute
infarction by neuroimaging or pathology (or in the absence of imaging)
Type 3b Delirium without CNS
injury
Transient non-focal (global) neurologic signs or symptoms (variable duration) without evidence of cell death by neuroimaging or pathology
The association of the neurologic event should be classified as:
□ Patient-related: (e.g., documentation of previous carotid or cerebrovascular disease, coagulopathy unrelated to surgical technique such as non-adherence with anti-coagulation medication resulting in an inappropriately high level of anti-
coagulation, related to illicit drug use, non-adherence with other medications, trauma, associated with sepsis)
□ Management-related: (e.g., over anti-coagulation or associated with the use of accessory assist device, hypotension or hypertension-related to surgical procedure)
□ Device-related: (e.g. secondary to pump thrombosis or device malfunction)
Abbreviations: CNS, central nervous system; MCS-ARC, Mechanical Circulatory Support, Academic Research Consortium; TIA, transient ischemic attack.
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some CNS injury may be directly attributable to these coa-
gulopathies. Thus, we are recommending that clinicians
attempt to establish device- and/or procedure-relatedness,
in addition to when and by what mechanism the CNS injury
occurred, if possible.
Taken together, these revised neurology event defini-
tions will lead to greater alignment with current concepts of
stroke, existing ARC statements, and a greatly improved
understanding of the frequency, spectrum, mechanisms,
and sequelae of CNS injury in the MCS population.
MCS-ARC device malfunction adverse event
Device malfunction is, perhaps, one of the most critical
events associated with durable MCS therapy.9,34−36 Owing
to the numerous components that comprise a durable MCS
device and variation in design among different durable
MCS devices, having a common definition that is expansive
and can accurately capture and categorize different compo-
nent failures is essential for clinicians and engineers to
have the highest degree understanding of the safety and reli-
ability of durable MCS systems. It is also essential that any
definition of device malfunction captures sufficiently granu-
lar data to be meaningful to clinicians and engineers to
determine the root cause of the malfunction and to develop
corrective strategies to resolve the identified issues.
Historically, greater attention has been given to highlight-
ing device malfunctions largely involving the pump, that is,
pump thrombosis.35,36 However, other components of the
durable MCS device, that is, percutaneous driveline or con-
troller, are critical for the proper function of the durable
MCS device and can fail, resulting in harm to the patient or
need for durable MCS device exchange.34 It is essential that
clinicians and health care providers capture all these events.
The new definition of device malfunction categorizes
events into major and minor severity (Table 5) (Supplemen-
tary Material Figure S4 online). The criteria for defining a
major event have been expanded to include several inter-
ventions or consequences to the patient not previously
captured. Device thrombosis is a separate category of
device malfunction denoted as major device malfunction-
device thrombus and as previously captured in the older
definition, it is categorized as suspected or confirmed. Crite-
ria to define a suspected event have been broadened to
include interventions or events not previously captured in
the previous definition.
As with each of the AE definitions, clinicians will be
asked whether the device malfunctions are patient-related,
management-related, or device-related.
MCS-ARC hemolysis adverse event
Hemolysis is now recognized as an important AE that is
closely associated with device malfunction, specifically,
pump thrombosis.37−39 Although hemolysis may occur in
patients supported with a durable MCS device from non-
device-related causes, these events are unusual. A bio-
marker such as lactate dehydrogenase (LDH), which is a
sensitive measure of the degree of hemolysis, has been
demonstrated to be predictive of future pump thromboses,
and elevated LDH levels significantly correlate with the
presence of pump thrombus at the time of pump exchange.
It is important to understand that different durable MCS
devices are associated with varying degrees of background
hemolysis, such that biomarkers like LDH may be mildly
elevated in patients supported with a durable MCS device
in the presence of normal pump function and appropriate
hemodynamic support. Previous data have supported an
LDH rise to greater than 2.5£ the upper limits of normal as
indicative of an abnormal degree of hemolysis and sugges-
tive of pump thrombosis.37,38 However, these data were
largely based on the experience of 1 type of continuous
flow-rotary pump. As the field moves forward and new
technology is introduced into clinical practice, biomarker
thresholds that define important levels of hemolysis for
individual pumps may need to be modified. We also believe
that a plasma-free hemoglobin > 20 mg/dl may be added as
another indicator of hemolysis. An LDH rise may falsely
Table 4 Classification of Acute Severity, Recovery and Long-Term Disability
Acute Severity 1. Mild neurologic dysfunction: NIHSS 0-5
2. Moderate neurologic dysfunction: NIHSS 6-14
3. Severe neurologic dysfunction: NIHSS ≥15
NOTE: Severity assessment should be performed at the time of diagnosis of any overt CNS injury (Types 1) to ensure
accurate classification
Stroke Recovery Stroke with complete recovery: A modified Rankin Score (MRS) at 30-90 days of 0 OR a return to the patient’s pre-
stroke baseline MRS, in the absence of any ongoing new symptoms due to the stroke.
Stroke Disability Fatal Stroke: Death resulting from a stroke where the cause of death is attributable to the stroke.
 Disabling stroke: An MRS ≥2 at 30-90 days with an increase of at least 1 point compared to the pre-stroke
baseline.
 Non-disabling stroke: An MRS <2 at 30-90 days, or ≥2 without an increase of at least 1 compared to the pre-
stroke baseline.
NOTE: Disability assessment applies only to subjects with overt CNS injury (Type 1) and should be performed at 90§
14 days after the stroke event.
Abbreviations: CNS, central nervous system; MRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale
(For Pediatric Patients the pediatric NIH SS will be used.)
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Table 5 MCS-ARC Device Malfunction Adverse Event
A device malfunction occurs when any component of the MCSD system ceases to operate to its designed performance specifications or otherwise fails to perform as intended.
Performance specifications include all claims made in the instructions for use.
Device malfunctions are further defined as major or minor:
Major Device Malfunction
Major device malfunction, otherwise known as failure, occurs when of one or more of the components of the MCSD system either directly causes or could potentially induce a
state of inadequate circulatory support (low cardiac output state) or death. A failure that was iatrogenic or recipient-induced will be classified as an Iatrogenic/Recipient-
Induced Failure. A device malfunction or failure is categorized as major when one of the following conditions occurs:
1. Death.
2. Hospitalization, emergency room visit or prolongation of hospitalization, or escalation of the level of care in an ongoing hospitalization (i.e., transfer to the intensive care
unit).
3. Life-threatening event (i.e., stroke or TIA, cardiac arrest, heart failure, syncope or near syncopal event, arrhythmia, etc.).
4. Results in significant disability or incapacity.
5. Requires an intervention to prevent impairment/injury including:
a. Urgent transplantation listing (immediate urgent listing for the transplant).
b. Pump replacement.
c. Pump explant.
d. Pump deactivation without explant or partial explant of components.
e. Breach of integrity of percutaneous lead requiring repair.
f. Operation to repair or replace any internal component of the circulatory support system.
g Procedure to repair or stent an outflow graft.
Note: Replacement of external controller that is done in an inpatient setting for logistical reasons, in an otherwise stable patient, should be considered a minor device mal-
function rather than major.
Minor Device Malfunction
Minor device malfunction includes inadequately functioning external components that require repair or replacement but do not result in 1a to g. Device malfunction does not
apply to routine maintenance including replacement of external controller, pneumatic drive unit, electric power supplies, batteries, and interconnecting cables that are not
related to a failed component.
Major Device Malfunction
Device thrombus: Intracorporeal device thrombus represents a special case of major device malfunction and can be categorized as a suspected device thrombus or confirmed
device thrombus. Device thrombus will be classified as suspected (see definition below) on the basis of clinical, biochemical, or hemodynamic findings or confirmed (see defini-
tion below) on the basis of device inspection or incontrovertible radiologic studies or absence of appropriate Doppler flow signals that confirm thrombus within the device or its
conduits that results in or could potentially induce circulatory failure.
1. Suspected device thrombus is a device-related malfunction in which clinical or MCSD parameters suggest thrombus on the blood-contacting components of the pump,
cannula, or grafts. Suspected device thrombosis will be defined as signs and symptoms to include at least 1 of the 3 following criteria:
□ Presence of major hemolysis (including elevation of biochemical markers of hemolysis; i.e., lactate dehydrogenase or plasma-free hemoglobin, or clinical evidence of
hemolysis; i.e., hemoglobinuria).
□ Presence of heart failure not explained by structural heart disease.
□ Abnormal pump parameters consistent with diminished pump output/pump efficiency/pump performance.
And;
Suspected device thrombus will be accompanied by 1 or more of the following events or interventions:
i. Death
ii. Stroke or TIA.
iii. Arterial non-CNS thromboembolism.
iv. De-novo need for inotrope therapy.
v. Treatment with intravenous anti-coagulation (i.e., heparin), intravenous thrombolytics (i.e., tPA), or intravenous anti-platelet therapy (i.e., eptifibatide, tirofiban).
vi. Pump replacement.
vii. Pump explantation with or without exchange.
viii.Pump deactivation without pump removal.
ix. Operation to repair or replace any internal component of the circulatory support system.
x. Urgent transplantation listing (immediate urgent listing for transplant).
2. Confirmed device thrombus is a major device-related malfunction in which thrombus is confirmed within the blood-contacting surfaces of device inflow cannula or outflow
conduit or grafts. This can be reported through direct visual inspection or by incontrovertible contrast radiographic evidence or by the absence of an appropriate Doppler
flow signal that results in or could potentially induce circulatory failure or result in thromboembolism.
Para conduit device thrombus represents a special case of device malfunction whereby thrombus obstructs the outflow graft from the pump. This should be classified as
major if the thrombus directly interferes with pump function by obstructing flow and if the pump is replaced because of the thrombus. The event should be classified as
minor if there is visible thrombus with the preserved function of the pump but requires surgical intervention (difficult to define minor when it requires surgical interven-
tion). In all instances, visual confirmation of the thrombus is sufficient for confirmation.
If a suspected device thrombus event is ultimately confirmed through visual inspection following pump replacement, urgent transplantation or on autopsy following death,
the event will be maybe reclassified to confirmed device thrombus.
The association of the device malfunction event should be classified as:
 Patient-related: (i.e., non-adherence with care of device or Instructions for Use, or its peripheral components, non-adherence with the anti-coagulation regimen, pro-
coagulation abnormalities)
 Management-related (i.e., surgical protocol deviation, sub-optimal anti-coagulation)
 Device-related: (i.e., detected in a device at explant or on contrast studies or associated with hemolysis or other controller data consistent with device malfunction)
Abbreviations: MCS-ARC, Mechanical Circulatory Support, Academic Research Consortium; MCSD, mechanical circulatory support device; TIA, transient ischemic attack.
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indicate hemolysis if due to hepatic or pulmonary injury;
therefore, the plasma-free hemoglobin level may substanti-
ate hemolysis. In certain cases, however, the plasma-free
hemoglobin elevation may also be inaccurate if the blood
draw is traumatic and thus, should be repeated. Hemolysis
as in the previous Intermacs definition has been categorized
as minor and major in the MCS-ARC definition (Table 6
and Supplementary Material Figure S5 online).
Minor hemolysis reflects the elevation of biomarkers
without clinical signs or symptoms and normal durable MCS
device function. Major hemolysis is associated with abnor-
mal pump function or clinical symptoms or signs. In the pre-
vious version of Intermacs, hemolysis was captured as a
triggered event, meaning that the event was automatically
recorded if the LDH level alone was above the threshold for
the definition, and no conscious effort had to be made by
clinicians to record the event. If the value was not entered,
then hemolysis as an event may have been missed, and if the
value was a false-positive, then the event was recorded even
if non-existent. We recommended that this event be tracked
as a specific consciously recorded event as opposed to auto-
matically. It is critical that centers interpret LDH values in
the context of the assay’s upper limits of normal.37,38
MCS-ARC right heart Failure adverse event
The incidence of right HF following LVAD implantation
varies from 3% to 35% depending on patient selection and
definition of right HF.40−43 In the overwhelming instances,
right HF is present at the time of LVAD implantation and
function worsens in the immediate peri-operative period
from changes in right ventricular function owing to intrao-
perative insults or changes in pulmonary vascular resistance
or both.40 In addition, LVAD unloading of the left ventricle
unloads the septal wall and reduces the septal contribution
to right ventricular function, causing further impairment of
right ventricular function.40−43 In a minority of cases, the
worsening of right heart function can lead to severe right
HF, requiring right ventricular assist device support
(RVAD) or prolonged pharmacologic support with inotropes
and/or pulmonary vasodilators.40−43 Right HF following
LVAD implantation that requires RVAD support signifi-
cantly reduces overall survival, increases morbidity, and
reduces the success of a bridge-to-transplant strategy. Over-
all survival for patients requiring continued RVAD support
is approximately 50% at 1 year and is significantly less than
that for patients requiring LVAD support alone.9,40−43
The occurrence of right HF evolved in Intermacs from a
recorded event to a condition that was automatically entered
on the basis of an algorithm of certain conditions or mani-
festations having been recorded. As a condition, the pres-
ence and severity of right HF were based on the presence of
clinical (ascites, edema, and elevated central venous pres-
sure or right atrial pressure) and echocardiographic imaging
findings and interventions required (diuretic or inotropic
agents) for the right heart. Although this strategy of defining
the right HF as a condition informed the investigator of late
manifestations, the working definition was cumbersome par-
ticularly for clinical trials attempting to identify a discrete
event. Therefore, the MCS-ARC definition of right HF is
now returning to an event-based entry process to identify
the right HF as an event following LVAD implantation
(Table 7 and Supplementary Material Figure S6 online).
Table 6 MCS ARC Hemolysis Adverse Event
Minor Hemolysis
A plasma-free hemoglobin value greater than 20 mg/dl or a serum LDH level greater than two and one-half times (2.5£) the upper limits
of the normal range at the implanting center occurring after the first 72 hours post-implant in the absence of clinical symptoms or
findings of hemolysis or abnormal pump function (see Major Hemolysis for a list of symptoms and findings) and thought not attribut-
able to laboratory error.
Major Hemolysis
A plasma-free hemoglobin value greater than 20 mg/dl or a serum LDH level greater than two and one-half times (2.5£) the upper limits
of the normal range at the implanting center occurring after the first 72 hours post-implant and associated with clinical symptoms or
findings of hemolysis or abnormal pump function. Major Hemolysis requires the presence of at least one of the following conditions:
 Hemoglobinuria (“tea-colored urine”)
 Anemia (decrease in hematocrit or hemoglobin level that is out of proportion to levels explainable by chronic illness or usual post-
VAD state)
 Hyperbilirubinemia (total bilirubin above 2 mg/dl, with predominately indirect component)
 Pump malfunction and/or abnormal pump parameters as per section on device malfunction
Note:
 Isolated LDH elevations should not be reported as hemolysis if attributable to laboratory error, hepatic or pulmonary dysfunction. If
suspected, confirmatory testing of LDH, LDH isoenzymes and plasma-free hemoglobin within 24 hours should be obtained to rule out
laboratory error.
 All causes of hemolysis should be reported regardless of whether they are thought attributable to the device or not.
The association of the hemolysis event should be classified as:
 Patient related: (i.e., hematologic abnormalities)
 Management related: (i.e., drug related, secondary pump or IABP related, pump malposition)
Device related: (i.e., related to pump thrombosis or device malfunction)
Abbreviations: IABP, intra-aortic balloon pump; LDH, lactate dehydrogenase; VAD, ventricular assist device.
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Table 7 MCS-ARC Right Heart Failure Adverse Event
Right Heart Failure
Early Acute Right Heart Failure
 Need for implantation of a temporary or durable RVAD (including ECMO) concomitant with LVAD implantation (RVAD implanted before
the patient leaving the operating room).
Early post-implant right heart failure
 Need for implantation of a temporary or durable RVAD (including ECMO) within 30 days following LVAD implantation for any duration
of time; or,
 Failure to wean from inotropic or vasopressor support or inhaled nitric oxide within 14 days following LVAD implantation or having to
initiate this support within 30 days of implant for a duration of at least 14 days.
○ The primary diagnosis of right heart failure is made by the presence of at least two of the following clinical findings:
& Ascites
& Functionally limiting peripheral edema (> 2+)
& Elevated estimated jugular venous pressure at least halfway up the neck in an upright patient.
& Elevated measured central venous pressure or right atrial pressure (≥16 mm Hg)
○ or is associated with at least one of the following manifestations:
& Renal failure with serum creatinine > 2£ baseline values.
& Liver injury with an elevation of at least 2£ upper limit normal in AST/ALT or total bilirubin > 2.0.
& SVO2 < 50%.
& Cardiac index < 2.2 liter/min/m2.
& Reduction in pump flow of > 30% from the previous baseline in the absence of mechanical causes such as cardiac tamponade or
tension pneumothorax.
& Elevated lactate >3.0 mmol/liter.
 Death occurring in patients within 14 days of LVAD implant who have not received an RVAD but who remain on inotropes or vasopres-
sors at the time of death and meet criteria for the diagnosis of Right Heart Failure on the basis of the above clinical findings (2 crite-
ria) or manifestations (1 criterion) will be considered to have early post-implant right heart failure at the time of death. The
contribution of early post-implant right heart failure to the death (primary or secondary) will be made by the clinical care team.
○ For pediatric patients, the diagnostic criteria above may be modified as follows:
& Primary diagnosis of RHF based on at least 2 of the following clinical findings
& Ascites
& Significant peripheral edema (+2)
& Elevated JVP (visible in an upright patient) or hepatomegaly (3+ cm below costal margin)
& Elevated CVP or RA pressure:
 For age 10−18 years: CVP > 14 mm Hg
 For age 5−10 years: CVP >12 mm Hg
 For age < 5 years: CVP > 10 mm Hg
& Or at least one of the following manifestations:
 Renal failure indicated by serum creatinine 1.5£ above baseline.
 Liver injury with an elevation of AST, ALT or total bilirubin of 2£ upper normal.
 Decrease in pump flow of 30% from a recent baseline in the absence of tamponade.
 We need to decrease the pump rate by 20% or more from a recent baseline owing to the poor filling of LVAD in a pulsatile
system.
 Cardiac Index < 2.2 liter/min/m2.
Late RHF
 Need for implantation of an RVAD (including ECMO) greater than 30 days after an LVAD implantation. This may occur within the index
hospitalization for LVAD implant or during subsequent rehospitalization for any diagnosis which resulted in a need for temporary or
permanent right-sided mechanical assist devices.
 Hospitalization that occurs greater than 30 days post-implant and which requires intravenous diuretics or inotropic support for at
least 72 hours and is associated with:
○ The diagnosis of right heart failure is made by the presence of at least two of the following clinical findings:
& Ascites
& Functionally limiting peripheral edema (>2+).
& Elevated estimated jugular venous pressure at least halfway up the neck in an upright patient.
& Elevated measured central venous pressure (>16 mm Hg).
○ or which is associated with at least one of the following manifestations:
& Renal failure with serum creatinine > 2£ baseline value
& Liver injury with an elevation of at least 2£ upper limit normal in AST/ALT or total bilirubin > 2.0
& A reduction in pump flow of > 30% from the previous baseline in the absence of tamponade
& SVO2 < 50%
& Cardiac index < 2.2 liter/min/m2
& Elevated lactate >3.0 mmol/liter
(continued on next page)
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The symptomatic, hemodynamic, and echocardiographic
criteria to qualify for right HF will be retained from the
original definition, however, a conscious decision to enter
this event with its date of diagnosis will be required and it
will no longer occur automatically. The new definition also
provides some guidance through the recording of the asso-
ciations with the right HF event to allow clinicians to iden-
tify pre-implant right HF leading to a planned vs unplanned
RVAD implant.
Other adverse events
The original Intermacs definition of renal dysfunction was
defined as either acute or chronic renal dysfunction, but the
severity of renal dysfunction was not collected. The defini-
tion of renal dysfunction has been upgraded to include the
severity of the renal compromise. In this newly proposed
MCS-ARC renal dysfunction AE definition, the severity of
renal dysfunction is sub-divided into 3 stages (Table 8).
Unlike other AEs addressed in this consensus statement, we
recommend that several other AEs that are tracked by Inter-
macs should continue to be included with little or no change
in the substance of their definitions or data needing to be
collected (Table 9 additional AEs). These include cardiac
arrhythmia; respiratory failure; venous thromboembolism;
wound dehiscence; arterial non-CNS thromboembolism,
hypertension, and hepatic dysfunction. The definition of an
occurrence of a psychiatric episode will follow the tradi-
tional diagnostic and statistical manual of mental disorders
classifications.
The association of some of these AEs as being patient-
related, management-related, or device-related in their ori-
gins will now be identified and collected. We recommend
elimination of the need to track the Intermacs AEs for myo-
cardial infarction, other AEs, and pericardial fluid collec-
tion. The event of cardiac tamponade will be captured
under the MSC-ARC bleeding AE.
Short-term or temporary MCS devices
In recent years, there has been an increase of interest in the
use of temporary MCS devices for specific sub-groups of
patients.44−47 Some cohorts that might benefit from tempo-
rary MCS devices are patients with myocardial infarction
resulting in cardiogenic shock, patients with acute or acute-
on-chronic left ventricular failure with cardiogenic shock
with specific etiologies of HF, and patients with right HF
(e.g., post-LVAD implantation or heart transplantation).44−47
The MCS-ARC recognizes the importance and increasing
usage of these devices and has, therefore, reformulated some
of the AE definitions for these devices, including hemolysis
and device malfunction. All other AE definitions for durable
MCS devices noted above will apply for short-term or tem-
porary MCS devices. Furthermore, because many devices
are inserted percutaneously, definitions of the vascular access
site AEs were adapted from the valve ARC.18
As of the date of publication, the short-term device defi-
nitions proposed in this consensus are specifically applica-
ble to the following technologies: Impella (CP, 5.0, LD,
RP) (Abiomed, Danvers, MA), Centrimag (Levitronix,
Waltham, MA), and TandemHeart (LivaNova, London,
 For pediatric patients, the criteria should be modified as follows.
○ Requirement for intravenous diuretics or inotropic support of at least 72 hours to treat right heart failure that was not present
continuously since implantation (must have been without intravenous diuretics and inotropic support for at least 7 consecutive
days at some time following implantation of LVAD)
& Diagnosis of RHF must be based on at least 2 of the following clinical findings
 Ascites
 Significant peripheral edema (+2)
 Elevated JVP (visible in the upright patient) or Hepatomegaly (3+ cm below costal margin)
 Elevated CVP or RA pressure
○ For age 10−18 years: CVP > 14 mm Hg
○ For age 5−10 years: CVP >12 mm Hg
○ For age < 5 years: CVP > 10 mm Hg
& Or at least one of the following manifestations
 Renal failure indicated by serum creatinine 1.5£ above baseline.
 Liver injury with elevation of AST, ALT or Total Bilirubin of 2£ upper normal.
 Decrease in pump flow of 30% from a recent baseline in the absence of tamponade.
 Need to decrease pump rate by 20% or more from a recent baseline because of poor filling of LVAD in a pulsatile system.
 Cardiac index < 2.2 liter/min/m2.
The association of the RHF event should be classified as:
Patient-related: (e.g., pre-implant right heart failure, volume overload secondary to non-adherence with medical management, severe
aortic regurgitation, cardiorenal syndrome, arrhythmia induced, pulmonary disease, elevated pulmonary vascular resistance).
Management-related: (e.g., related to implant surgery, volume overload, inotropic agent withdrawal).
Device-related: (e.g., associated with Pump malfunction, outflow graft compromise).
Abbreviations: ALT, alanine transaminase; AST, aspartate transaminase; CVP, central venous pressure; ECMO, extracorporeal membrane oxygenation;
JVP, Jugular venous presure; LVAD, left ventricular assist device; RA, right atrium; RHF, right heart failure; RVAD, right ventricular assist device; SVO2,
mixed venous oxygen saturation.
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United Kingdom), but not for the intra-aortic balloon pump
and extracorporeal membrane oxygenation (Table 10).
Discussion
This report summarizes an international and collaborative
effort to update AE definitions that apply to the field of
MCS. The updated AEs have been defined by domain
experts in the field of cardiac surgery, cardiology, neurol-
ogy, infectious diseases, and engineering. Where possible,
the updated AE definitions have taken advantage of previ-
ously published definitions of AEs developed by the ARC
for cardiac surgery, specifically those developed for the
AEs for bleeding and neurologic events, for developing
more global harmonization of AEs within the cardiovascu-
lar field, in general. The MCS-ARC solicited input from
North American and international experts through the part-
nership with the STS and ISHLT Mechanically Assisted
Circulatory Support Registry, the Japanese Registry for
Mechanically Assisted Circulatory Support, and European
Registry for Patients with MCS. Global harmonization of
AE definitions is critical to the MCS field as more clinical
trials evaluating safety with new devices are contemplated
in centers around the World. In addition, AE definitions
were modified for Pedimacs applications, where
appropriate.
Where feasible, existing Intermacs definitions served as
a solid foundation for the new MCS-ARC definitions, with
the goal of not creating an additional burden on data collec-
tion. However, there were cases where more granularity
was requested by domain experts, especially as the field
considers clinical trials with MCS devices that are targeted
to a population of patients with ambulatory HF that are
characterized by Intermacs Profile 4‒7.
Importantly, the MCS-ARC group agreed that for each
major AE, there should be a determination regarding the
associations that contributed to the event. This would be
expressed as either patient-related, management-related, or
device-related. The group believed that this additional
insight to the probable contributory factors to the AE would
provide critical information regarding patients’ non-adher-
ence or failure to follow the manual of operations for the
device as a potential cause for an event, such as device mal-
function. It will also help to guide the interpretation of the
factors that are related to thrombosis when protocols for
anti-coagulation cannot be followed. It is also possible that
a significant AE burden exists pre-operatively in some
patients with an MCS device and that these events are trans-
mitted to the post-operative period and recorded in data-
bases as new early events after the MCS device is
implanted. The designation of AEs being patient-related
may clarify these situations. For example, this association
will aid in identifying those patients who present to surgery
with significant pre-existing right HF and thus, can be iden-
tified as having patient-related factors as a cause for right
HF after surgery. This helps to clarify the difference
between a planned and unplanned RVAD at the time of sur-
gery. Similarly, other examples exist in cases where pre-
operative renal, hepatic, neurologic, and pulmonary compli-
cations are present pre-operatively.
Table 8 MSC-ARC Renal Dysfunction Adverse Event
Acute Renal Dysfunction
 Stage 1
○ Increase in serum creatinine to 150% to 199% (1.5−1.99£ increase compared with baseline) or increase of > 0.3 mg/dl (> 26.4
mmol/liter) or
○ Urine output < 0.5 ml/kg/h for > 6 but < 12 hours.
 Stage 2
○ Increase in serum creatinine to 200% to 299% (2.0£−2.99£ increase compared with baseline) or
○ Urine output < 0.5 ml/kg/h for > 12 but < 24 hours.
 Stage 3
○ Increase in serum creatinine to >300% (>3£ increase compared with baseline) or
○ Serum creatinine of > 4.0 mg/dl (>354 mmol/liter) with an acute increase of at least 0.5 mg/dl (44 mmol/liter) or
○ Urine output <0.3 ml/kg/h for >24 hours or
○ Anuria for >12 hours or
○ Need for renal replacement therapy (includes dialysis or ultrafiltration) regardless of above criteria.
Chronic Renal Dysfunction
An increase in serum creatinine of 2 mg/dl or greater above baseline, or requirement for renal replacement therapy, either of which is
sustained for at least 90 days.
The association of the renal dysfunction event should be classified as follows:
 Patient-related: (e.g., non-adherence to medical therapy resulting in renal dysfunction).
 Management-related: (e.g., overprescribing of diuretic therapy or administration of renal toxic drugs or contrast agents that result
in renal dysfunction).
 Device-related: (e.g., device failure resulting in renal dysfunction).
Abbreviations: CNS, central nervous system; DSM, diagnostic and statistical manual of mental disorders; MCS-ARC, mechanical circulatory support, aca-
demic research consortium; VAD, ventricular assist device.
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The success of the utilization of the new MCS-ARC
definitions for Intermacs will depend not only on global
acceptance by clinicians, device manufacturers, and the
regulatory agencies but also on the development of a clear
and detailed user guide. This guide will need to provide
guidance to the coordinators and clinicians who make
decisions about each AE and whether the clinical presen-
tation meets the definitions. Although, in many cases,
these definitions seem complex, in reality, filling out
Intermacs fields will be far simpler utilizing drop-down
boxes for choices. In many cases, the exact forms for data
collection may require only modest modifications, with
Table 9 Other Adverse Events
MCS-ARC Cardiac Arrhythmias
Any documented arrhythmia that results in clinical compromise (e.g., abnormal VAD function [e.g., diminished VAD flow or suction
events], oliguria, pre-syncope or syncope, angina, dyspnea), or requires hospitalization or treatment (drug therapy, defibrillation, car-
dioversion, ICD therapy (e.g., shock or anti-tachycardia pacing) or arrhythmia ablation procedure). Cardiac arrhythmias are classified
as 1 of 2 types:
The association of the cardiac arrythmia event should be classified as:
1) Sustained ventricular arrhythmia resulting in clinical compromise, or requiring hospitalization or drug treatment, defibrillation, car-
dioversion, ICD therapy, or arrhythmia ablation procedure.
2) Sustained supraventricular arrhythmia resulting in clinical compromise, or requiring hospitalization or drug treatment, cardioversion,
ICD therapy, or arrhythmia ablation procedure.
 Patient-related: (e.g., recurrence of pre-operative arrhythmia non-adherence with medications).
 Management-related: (e.g., related to uncorrected electrolyte imbalance, Swan Ganz malposition, secondary to cardiac
tamponade).
 Device-related: (e.g., Pump malfunction, malposition of pump, or inflow cannula).
MCS-ARC Respiratory Failure
Impairment of respiratory function requiring reintubation, tracheostomy, or the inability to discontinue ventilatory support within
6 days (144 hours) post-VAD implant. This excludes intubation for reoperation or temporary intubation for diagnostic or therapeutic
procedures.
The association of the respiratory failure event should be classified as follows:
 Patient-related: (e.g., non-adherence to medical therapy resulting in respiratory failure).
 Management-related: (e.g., inadequate diuretic therapy resulting in respiratory dysfunction).
 Device-related: (e.g., device failure resulting in respiratory dysfunction).
MCS-ARC Venous Thromboembolism
Evidence of venous thromboembolic event (e.g., deep vein thrombosis, pulmonary embolism) by standard clinical and laboratory testing.
MCS-ARC Wound Dehiscence
Disruption of the apposed surfaces of a surgical incision, excluding infectious etiology, and requiring surgical repair.
MCS-ARC Arterial non-CNS Thromboembolism
An acute systemic arterial perfusion deficit in any non-cerebrovascular organ system due to thromboembolism confirmed by 1 or more of
the following: This definition excludes neurologic events.
1) standard clinical and laboratory testing
2) operative findings
3) autopsy findings
MCS-ARC Hepatic Dysfunction
An increase in any two of the following hepatic laboratory values (total bilirubin, AST, and ALT) to a level greater than 3 times the upper
limit of normal for the hospital, beyond 14 days post-implant (or if hepatic dysfunction is the primary cause of death).
MCS-ARC Hypertension: Adult
New-onset blood pressure elevation greater than or equal to 140 mm Hg systolic or 90 mm Hg diastolic (pulsatile pump) or 110 mm Hg
mean pressure (rotary pump).
Pediatric:
Hypertension is defined as systolic, diastolic, or mean blood pressure greater than the 95th percentile for age which requires the addi-
tion of a new IV or oral therapy for management. The event shall be considered resolved on the discontinuation of the treatment.
MCS-ARC Psychiatric Episode:
Disturbance in thinking, emotion or behavior that causes substantial impairment in functioning or marked subjective distress and
requires intervention. Intervention is the addition of new psychiatric medication, hospitalization, or referral to a mental health profes-
sional for treatment. Suicide is included in this definition.
The psychiatric event should be classified according to the DSM 5 classification:
 Axis I: Clinical disorders, including anxiety disorders, mood disorders, schizophrenia and other psychotic disorders.
 Axis II: Personality disorders and mental retardation.
 Axis III: General medical conditions.
 Axis IV: Psychosocial and environmental problems.
Abbreviations: CNS, central nervous system; DSM, diagnostic and statistical manual of mental disorders; MCS-ARC, Mechanical Circulatory Support, Aca-
demic Research Consortium; VAD, ventricular assist device.
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more detailed instructions on how to determine the pres-
ence of an AE.
This is an effort to once again harmonize and refine defi-
nitions of AEs. Furthermore, the MCS-ARC has tried to
improve the granularity of some AEs either by changing
definitions or by adding a possible attribution. MCS will
continue to evolve in the future, and indeed the MCS-ARC
intends to promote this and improve intertrial comparability
between devices because of harmonized end-points.
A major addition to these definitions included recogni-
tion of the need to track events in patients receiving
temporary MCS as none existed to date except for the
Impella percutaneous pump managed by the Abiomed.
Percutaneous complications were included utilizing the val-
vular ARC definitions as well as definitions from the
Abiomed registry.
To date, considerable experience has been obtained in
the field of MCS. Major safety issues remain with MCS
devices and the overall AE burden for patients receiving
durable and temporary MCS devices remains high. Cur-
rently, bleeding, stroke, device infection, device malfunc-
tion, and right HF remain the major obstacles to broader
Table 10 Short-Term or Temporary Mechanical Circulatory Support (MCS) Device-Specific Adverse Events
Hemolysis
Minor Hemolysis: a plasma-free Hgb value >20 but < 40 mg/dl or a serum lactate dehydrogenase (LDH) level greater than 2.5£ the
upper limits of the normal range at the implanting center occurring after the first 72 hours post-implant in the absence of clinical
symptoms or findings of hemolysis or abnormal pump function
Major Hemolysis: Two plasma-free Hgb values > 40 mg/dl with the 2 readings taken within a single 48-hour period. If plasma-free
Hgb not available, hemolysis will be defined by the combination of clinical signs (see below) and laboratory testing including
increased LDH, increased bilirubin and decreased hemoglobin (all 3 required). It requires the presence of one or more of the following
conditions:
 Hemoglobinuria
 Anemia
 Hyperbilirubinemia
 Pump malfunction and/or abnormal pump parameters
Vascular Access Site Adverse Events
These Adverse events (AEs) related only to devices inserted through the percutaneous route.
Proposed Definitions:
Minor Complications: Any of the events below that required a diagnostic investigation to be confirmed and were treated without the
need for surgical intervention.
1. Pseudo-aneurysm
2. Arteriovenous fistula
3. Vessel thrombosis/Distal embolization
4. Vessel dissection, perforation or rupture
5. Vessel stenosis
6. Cannulation site bleeding
7. Limb ischemia
8. Vascular access site infection
Major Complications: Any of the events below that required a diagnostic investigation to be confirmed and required surgical or endo-
vascular intervention.
1. Pseudo-aneurysm
2. Arteriovenous fistula
3. Vessel thrombosis/Distal embolization
4. Vessel dissection, perforation or rupture
5. Vessel stenosis
6. Cannulation site bleeding (would have to fulfill durable device bleeding definition)
7. Limb ischemia
8. Vascular access site infection
Device Malfunction
Device Failure: Unexpected and sudden stop of the functioning of the pump that cannot be corrected by restarting the pump following
recommended instructions. It can be caused by the failure of any of the components of the system and impacts negatively on the treat-
ment of the patient. Includes device malfunction due to device thrombus.
Device Malfunction: Unexpected change in device performance that is contradictory to the labeling and/or negatively impacts the
treatment of the patient, when the device is used in adherence to the instructions for use (IFU). A stoppage that can be corrected by
restarting the pump would fall under this category. Includes device malfunction due to device thrombus.
The association of the Short-Term or Temporary MCS-Specific Adverse Event should be classified as follows:
 Patient-related: (e.g., non-adherence to medical therapy)
 Management-related: (e.g., improper anti-coagulation management resulting in thrombosis or stroke)
 Device-related: (e.g., device failure)
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adoption of this therapy, both for existing indications and
for newer indications for patients with less-advanced stages
of HF. We believe that the new MCS-ARC definitions pre-
sented here, largely focusing on the 5 major AEs associated
with MCS therapy, provide an updated platform in which to
assess MCS device therapy. Limitations in previous defini-
tions were recognized and evaluated by experts in the field
with modifications made to nearly all definitions. We
believe that the adoption of new MCS-ARC definitions for
AEs will contribute to improved patient outcomes and
MCS device development.
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